Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Stock Information for Translate Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Translate Bio Inc.

Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
Translate Bio Appoints Robert Meyer, MD, to its Board of Directors
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT(TM))
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
Translate Bio to Participate in Upcoming Investor Conferences
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
Translate Bio Announces Pricing of Initial Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.